John A. Thompson

Publications

3 shown

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer , Christina Lacchetti , Bryan J. Schneider +26 more

Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint i...

2018 Journal of Clinical Oncology 3484 citations

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins , Sofiya Latifyan , Gerasimos P. Sykiotis +14 more

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-...

2019 Nature Reviews Clinical Oncology 2064 citations

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul Nghiem , Shailender Bhatia , Evan J. Lipson +28 more

BackgroundMerkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carci...

2016 New England Journal of Medicine 1214 citations

Researcher Info

h-index: 3
Publications: 3
Citations: 6,762
Institution: American Society of Clinical Oncology

External Links

Google Scholar

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.

Publications

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Frequent Co-Authors

Julie R. Brahmer

Christina Lacchetti

Bryan J. Schneider

Michael B. Atkins

Kelly Brassil

Jeffrey M. Caterino

Researcher Info

External Links

Impact Metrics